What Are Your Expectations for Risk Prediction Tools?
作者信息
Sotomi Yohei, Hikoso Shungo, Sakata Yasushi
机构信息
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
出版信息
JACC Asia. 2022 Apr 26;2(3):351-353. doi: 10.1016/j.jacasi.2022.01.003. eCollection 2022 Jun.
Abstract
摘要
相似文献
1
What Are Your Expectations for Risk Prediction Tools?
JACC Asia. 2022 Apr 26;2(3):351-353. doi: 10.1016/j.jacasi.2022.01.003. eCollection 2022 Jun.
2
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
J Am Heart Assoc. 2020 Aug 18;9(16):e017109. doi: 10.1161/JAHA.120.017109. Epub 2020 Aug 11.
3
Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients.
JACC Asia. 2022 Apr 26;2(3):341-350. doi: 10.1016/j.jacasi.2021.12.009. eCollection 2022 Jun.
4
Bivalirudin versus Heparin on Net Adverse Clinical Events, Major Adverse Cardiac and Cerebral Events, and Bleeding in Elderly Chinese Patients Treated with Percutaneous Coronary Intervention.
Tohoku J Exp Med. 2024 Mar 6;262(2):115-124. doi: 10.1620/tjem.2023.J085. Epub 2023 Oct 12.
5
Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis.
Circ Cardiovasc Interv. 2022 Nov;15(11):906-914. doi: 10.1161/CIRCINTERVENTIONS.122.012245. Epub 2022 Nov 15.
6
Risk of bleeding after percutaneous coronary intervention and its impact on further adverse events in clinical trial participants with comorbid peripheral arterial disease.
Int J Cardiol. 2023 Mar 1;374:27-32. doi: 10.1016/j.ijcard.2022.12.009. Epub 2022 Dec 7.
7
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10.
8
Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
BMC Cardiovasc Disord. 2018 May 2;18(1):78. doi: 10.1186/s12872-018-0820-6.
9
Impact of left ventricular ejection fraction and medication adherence on major adverse cardiac events during the first year after successful primary percutaneous coronary interventions.
J Clin Nurs. 2016 Apr;25(7-8):1101-11. doi: 10.1111/jocn.13109. Epub 2015 Dec 27.
10
Prognostic Value of Machine-Learning-Based PRAISE Score for Ischemic and Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
J Am Heart Assoc. 2023 Apr 4;12(7):e025812. doi: 10.1161/JAHA.122.025812. Epub 2023 Mar 28.
引用本文的文献
1
Individual acute-phase bleeding and thrombotic risk balance assessment in patients undergoing percutaneous coronary intervention for acute myocardial infarction.
Am Heart J Plus. 2023 Mar 17;28:100292. doi: 10.1016/j.ahjo.2023.100292. eCollection 2023 Apr.
本文引用的文献
1
Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients.
JACC Asia. 2022 Apr 26;2(3):341-350. doi: 10.1016/j.jacasi.2021.12.009. eCollection 2022 Jun.
2
Practical Assessment of the Tradeoff between Fatal Bleeding and Coronary Thrombotic Risks using the Academic Research Consortium for High Bleeding Risk Criteria.
J Atheroscler Thromb. 2022 Aug 1;29(8):1236-1248. doi: 10.5551/jat.62999. Epub 2021 Sep 15.
3
Prevalence of the Japanese high bleeding risk criteria and its prognostic significance for fatal bleeding in patients with acute myocardial infarction.
Heart Vessels. 2021 Oct;36(10):1484-1495. doi: 10.1007/s00380-021-01836-9. Epub 2021 Mar 20.
4
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention - From the CREDO-Kyoto Registry Cohort-3.
Circ J. 2021 May 25;85(6):769-781. doi: 10.1253/circj.CJ-20-0836. Epub 2020 Dec 8.
5
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
JACC Cardiovasc Interv. 2020 Oct 12;13(19):2251-2262. doi: 10.1016/j.jcin.2020.06.023. Epub 2020 Sep 16.
6
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease.
Circ J. 2020 Apr 24;84(5):831-865. doi: 10.1253/circj.CJ-19-1109. Epub 2020 Mar 13.
7
Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials.
Cardiovasc Interv Ther. 2020 Jul;35(3):250-258. doi: 10.1007/s12928-019-00613-w. Epub 2019 Aug 17.
8
Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.
Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22.
9
Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention.
Thromb Haemost. 2019 Jul;119(7):1182-1193. doi: 10.1055/s-0039-1688792. Epub 2019 May 12.
10
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores.
J Am Heart Assoc. 2018 May 22;7(11):e008708. doi: 10.1161/JAHA.118.008708.
Zotero 插件